Table 2 KEGG pathway analysis of the DMGs in plasma cf-DNA in different stage of HCC developmen
Stage | Term | Count | % | PValue | Genes |
|---|---|---|---|---|---|
Early | hsa04080:Neuroactive ligand-receptor interaction | 9 | 4.71 | 1.35E-03 | HTR1A,S1PR5,HTR7,GIPR,GRIK4,P2RY6,MTNR1B,GABBR1,ADRB1 |
hsa00150:Androgen and estrogen metabolism | 3 | 1.57 | 4.02E-02 | LCMT2,SRD5A3,SULT2B1 | |
hsa00140:Steroid hormone biosynthesis | 3 | 1.57 | 5.96E-02 | CYP1B1,SRD5A3,SULT2B1 | |
Middle | hsa04020:Calcium signaling pathway | 6 | 2.87 | 2.61E-02 | TNNC2,AVPR1A,ITPR3,PDE1C,BST1,ADRB3 |
hsa05200:Pathways in cancer | 7 | 3.35 | 9.31E-02 | RARA,SHH,GSTP1,PAX8,WNT10B,MMP9,APC2 | |
hsa05217:Basal cell carcinoma | 3 | 1.44 | 9.79E-02 | SHH,WNT10B,APC2 | |
hsa04080:Neuroactive ligand-receptor interaction | 6 | 2.87 | 9.82E-02 | GPR35,AVPR1A,NPBWR1,VIPR1,ADRB3,S1PR5 | |
Late | hsa04080:Neuroactive ligand-receptor interaction | 9 | 3.9 | 1.15E-03 | HTR2C,GABRG3,MLNR,GPR83,ADRA1A,S1PR4,GALR2,ADORA3,ADRB3 |
hsa05200:Pathways in cancer | 8 | 3.46 | 1.88E-02 | FGF8,CDKN2A,WNT10A,RET,SPI1,BMP2,MMP9,BCR |